RhumbLine Advisers
KMTS

RhumbLine Advisers’s Kestra Medical Technologies KMTS Stock Holding History

RhumbLine Advisers’s Portfolio KMTS Stock Details KMTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$784K Buy
30,832
+4,494
+17% +$94.1K ﹤0.01% 2480
2026
Q1 		$525K Buy
26,338
+10,584
+67% +$249K ﹤0.01% 2581
2025
Q4 		$418K Buy
15,754
+2,829
+22% +$72.9K ﹤0.01% 2781
2025
Q3 		$307K Buy
12,925
+874
+7% +$15.6K ﹤0.01% 2979
2025
Q2 		$200K Buy
+12,051
New +$263K ﹤0.01% 3229

Other funds holding KMTS

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

RhumbLine Advisers's KMTS Position: Q2 2026 in Review

RhumbLine Advisers increased its Kestra Medical Technologies (KMTS) stake by 17% in Q2 2026, buying an estimated $94.1K and bringing the position to 30,832 shares worth $784K. The position accounts for ﹤0.01% of the portfolio, ranked #2480.

RhumbLine Advisers first reported a position in KMTS in Q2 2025 and has held it in 5 quarters since. 109 funds tracked by Wall St. Rank hold KMTS as of Q2 2026.

  • RhumbLine Advisers held 30,832 shares of Kestra Medical Technologies worth $784K as of Q2 2026.
  • RhumbLine Advisers bought 4,494 Kestra Medical Technologies shares in Q2 2026, an estimated $94.1K.
  • Kestra Medical Technologies made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2480 holding.
  • RhumbLine Advisers first reported a position in Kestra Medical Technologies in Q2 2025 and has held it in 5 quarters since.
  • 109 funds tracked by Wall St. Rank held Kestra Medical Technologies as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.